Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Employment agrmnt
TCR2 THERAPEUTICS INC. (TCRR) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/01/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "FOURTH amended and restated CERTIFICATE OF INCORPORATION OF TCR 2 Therapeutics Inc.",
"SECOND Amended and Restated BY-LAWS OF TCR 2 THERAPEUTICS INC. ARTICLE I OFFICES SECTION 1.1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, Corporation Trust Center, Wilmington, Delaware 19801, and said corporation shall be the registered agent of this corporation in charge thereof. SECTION 1.2. OTHER OFFICES. The corporation may have other offices, either within or without the State of Delaware, at such place or places as the board of directors of the corporation may from time to time appoint or the business of the corporation may require. ARTICLE II MEETING OF STOCKHOLDERS SECTION 2.1. PLACE OF MEETINGS. Meetings of the stockholders shall be held at such place, either wit..."
05/24/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Assignment of Lease by and between TCR2 Therapeutics Inc. and AstraZeneca Pharmaceuticals LP",
"Lease Modification Agreement by and between TCR2 Therapeutics Inc. and ARE-Maryland No. 31, LLC"
05/11/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., May 11, 2023 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies’ complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the war on cancer,” said Garry Menzel, Ph.D., Presiden..."
03/23/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update • TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors • Following the expected Q2 2023 closing of the all-stock transaction, the combined company's cash runway is expected to extend into 2026 CAMBRIDGE, Mass., March 23, 2023- TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update. “Focus and specialization are critical in the cell therapy space. The strategic combination with Ad..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Exhibit 2.1    EXECUTION VERSION   AGREEMENT AND PLAN OF MERGER   BY AND AmONG   Adaptimmune therapeutics plc,   cm Merger sub, Inc.   AND   tcr 2 therapeutics inc.",
"Agreement”) is made and entered into as of March 5, 2023 , by and among Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales, TCR 2 Therapeutics Inc. , a Delaware corporation and [STOCKHOLDER] . Each of Parent, the Company and the Stockholder are sometimes referred to as a “Party” and collectively as the “Parties",
"VOTING AND SUPPORT AGREEMENT   This Voting and Support Agreement is made and entered into as of March 5, 2023 , by and among  Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales,  TCR 2 Therapeutics Inc. , a Delaware corporation and  [SHAREHOLDER] . Each of Parent, the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Merger Agreement .   RECITALS   A.              Concurrently with the execution and delivery of this Agreement, Parent, the Company and CM Merger Sub, Inc...",
"FIRST AMENDMENT TO EMPLOYMENT AGREEMENT",
"Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST",
"of Section 27 A of the Securities Act of 1933",
"significant operational advantages"
01/05/2023 8-K Quarterly results
01/03/2023 8-K Quarterly results
11/08/2022 8-K Quarterly results
10/14/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/28/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma - Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit - Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel",
"Copy of TCR2 Therapeutics Inc. slide presentation"
08/08/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/22/2022 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., March 22, 2022 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the fourth quarter ended December 31, 2021 and provided a corporate update. "Consistent execution throughout the last year has positioned TCR2 for a series of important readouts as we accelerate our clinical progress in 2022," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "We were able to successfully conclude the dose escalation portion of our ongoing gavo-cel Phase 1/2 clinical trial with the identification of a RP2D and ..."
11/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2021 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
11/01/2021 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits  Interactive Data
Docs: "TCR 2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity"
10/22/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
10/20/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TCR2 Therapeutics Reviews Pipeline and Strategy at R&D Day - gavo-cel recommended Phase 2 dose identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of platform into autoimmune diseases with TRuC Tregs - TCR2 to host a webcast on Wednesday, October 20 at 8:00a.m. ET",
"MPM MPM MPM MPM MSLN"
09/17/2021 8-K Quarterly results
08/26/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/30/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among TCR2 Therapeutics Inc., Goldman Sachs & Co. LLC, Jefferies LLC, Piper Sandler & Co. and BMO Capital Markets, as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"TCR 2 Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., Jan. 19, 2021 — TCR 2 Therapeutics Inc. , a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. TCR 2 also intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offering are to be sold by TCR 2 . The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Goldman Sachs & Co...",
"TCR 2 Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock CAMBRIDGE, Mass., Jan. 19, 2021 — TCR 2 Therapeutics Inc. , a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share. TCR 2 also granted the underwriters a 30-day option to purchase up to an additional 688,524 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $140.0 million,..."
01/19/2021 8-K Quarterly results
12/14/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TCR 2 Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors",
"Copy of TCR2 Therapeutics Inc. slide presentation"
11/12/2020 8-K Quarterly results
Docs: "Cash Position: TCR 2 ended the third quarter of 2020 with $246.7 million in cash, cash equivalents, and investments compared to $158.1 million as of December 31, 2019. Net cash used in operations was $10.8 million for the third quarter of 2020 compared to $10.1 million for third quarter of 2019. TCR 2 continues to project net cash use of $65-70 million for 2020. • R&D Expenses: Research and development expenses were $12.8 million for the third quarter of 2020 compared to $11.4 million for the third quarter of 2019. The increase in R&D expenses is primarily related to increase in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110. • G&A Expenses: General and administrative expense..."
10/02/2020 8-K Quarterly results
08/12/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy